Prahallad, Anirudh

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 2,051

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 888

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell

TGF-β signaling in diseasesLung Cancer Treatments and Mutations

Cited by 430

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 320

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 304

PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs

Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 168

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 39

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer

Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T., Ruddy, D., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 30

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells

Ressa, A., Bosdriesz, E., de Ligt, J., Mainardi, S., Maddalo, G., Prahallad, A., Jager, M., de la Fonteijne, L., Fitzpatrick, M., Groten, S., et al. (2018) · Molecular & Cellular Proteomics

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 17